-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT'S PARTNER OLLIN BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA WITH SUPERIOR OUTCOMES FROM A RANDOMIZED HEAD-TO-HEAD STUDY OF IBI324 COMPARED TO FARICIMAB (VABYSMO®) IN DIABETIC MACULAR EDEMA AND WET AGE-RELATED MACULAR DEGENERATION

Reuters·01/09/2026 00:00:00

Please log in to view news